Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Phase Distribution

Ph phase_1

40%

Ph phase_2

20%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (40.0%)

Phase 21 (20.0%)

Phase 32 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501

completedphase_3

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268

completedphase_3

Clinical Trials (5)

Showing 5 of 5 trials

NCT04427501Phase 2

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Completed

NCT05780268Phase 3

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed

NCT04501978Phase 3

ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed

NCT04537910Phase 1

A Study of LY3819253 (LY-CoV555) in Healthy Participants

Completed

NCT04411628Phase 1

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5